US2024002947A1PendingUtilityA1
Method of predicting risk of recurrence of cancer
Assignee: THE PROVOST FELLOWS SCHOLARS AND OTHER MEMBERS OF BOARD OF TRINITY COLLEGE DUBLINPriority: Sep 19, 2014Filed: Dec 15, 2022Published: Jan 4, 2024
Est. expirySep 19, 2034(~8.1 yrs left)· nominal 20-yr term from priority
G01N 33/57515G01N 33/5758C12Q 1/6886G01N 33/57415G01N 33/57484A61K 31/519C12Q 2600/158C12Q 2600/118C12Q 2600/106A61P 35/00A61P 35/02A61P 35/04
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.
Claims
exact text as granted — not AI-modified1 . A method of predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least four genes, or proteins encoded by said genes, selected from FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least four genes, or proteins encoded by said genes, correlates with increased risk of recurrence of cancer compared with an individual with cancer who does not exhibit positive expression of the at least four genes or proteins encoded by those genes.
2 - 23 . (canceled)Join the waitlist — get patent alerts
Track US2024002947A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.